About Omniome
Omniome is a Healthcare company based in San Diego (United States) founded in 2013, and was acquired by PacBio in July 2021. Genome sequencing platform is provided for clinical diagnostics. Omniome has raised $160.23 million across 7 funding rounds from investors including PacBio, Gates Foundation and Arch Venture Partners. The company has 164 employees. Its chief executive, as recorded, is Dave Mullarkey. Its focus areas include Life Sciences, Genomics, Genomics Services and Sequencing. Its legal entity is OMNIOME, INC. Its competitors include PacBio, Complete Genomics and Bionano; 3 of its 3 listed competitors have raised funding.
Company details
Omniome was founded in 2013 and is headquartered in San Diego, United States. The company operates in the biotechnology sector, offering a genome sequencing platform based on Sequencing By Binding (SBB) technology. This platform supports nucleotide and DNA matching for clinical samples, with applications in cancer diagnostics, single-cell sequencing, and analysis of genome regions susceptible to errors. Services are extended to various clinical sequencing needs.
- Headquarters San Diego, United States
- Employees 164
- Stage Acquired
- SectorsHealthcare
- Phone•••• ••••
- Website omniome.com
- Social LinkedIn X
- Acquired by PacBio (Jul 2021)
- Legal Name Omniome, Inc.
Funding Insights of Omniome
Omniome has successfully raised a total of $160.23M across 7 strategic funding rounds. The most recent funding activity was a Series C round of $60 million completed in December 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $160.23M
- Total Rounds 7
- Last Round Series C — $60M
- First Round $225,000
(May 2014)
- Investors Count 12
All 7 funding rounds of Omniome with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2019 | $60M | Series C | – | Detong Capital | |
| Feb 2019 | $40M | Series B | – | – | – |
| Jul 2018 | $60M | Series B | – | Decheng Capital, Hillhouse | |
| Jun 2016 | Series A | – | – | ||
| Jun 2014 | Seed | – | EvoNexus | – | |
| Jun 2014 | Seed | – | DCVC | – | |
| May 2014 | $225,000 | Seed | – | – | – |
13 investors in total: 13 institutional.
Investors in Omniome
Omniome has secured backing from 13 investors, including venture fund and institutional investors. Prominent investors backing the company include PacBio, Gates Foundation and Arch Venture Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
| dtcap.com | ||||
Venture capital firm focused on life science companies | 1986 | archventure.com | Chicago, United States | |
Venture capital firm focused on life science and technology sectors | decheng.com | Shanghai, China | ||
Life science & tech focused VC firm investing in the US | domainvc.com | Princeton, United States | ||
Early-stage tech and life sciences focused VC firm investing primarily in the US | biomaticscapital.com | Seattle, United States | ||
Corporate backed venture capital firm investing in life sciences sector | nanfunglifesciences.com | San Francisco, United States | ||
Early stage life sciences sectors focused VC firm investing in the US | altitudelsv.com | Kirkland, United States | ||
Global private equity investments are managed with long-term focus. | hillhouseinvestment.com | New York, United States | ||
Investments are made in innovative technology companies by Lam Capital. | lamcapital.com | |||
12-18 month incubation programs are provided for startups in California. | evonexus.org | San Diego, United States |
Investor details for Omniome
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Omniome
60 people are tracked at Omniome (27 in leadership, 8 in board & advisors, 25 in team); the tracked headcount is 164.
| Name | Role | Group |
|---|---|---|
Dave Mullarkey | CEO & President | Leadership |
Christian Henry | CEO & President | Leadership |
Mark Van Oene | COO | Leadership |
Natalie Welch | Chief People Officer | Leadership |
Michele Farmer | Chief Accounting Officer | Leadership |
Marybeth Blood | Director, Content And Marketing Programs | Leadership |
Mathieu Foquet | Director | Leadership |
Elizabeth Tseng | Associate Director, Product Marketing, Applications | Leadership |
Jim Gibson | Chief Financial Officer | Leadership |
Caleb McCanne | Associate Director, Global Commercial Operations | Leadership |
Nicole M Ellis-Ovadia | Associate Director Segment Marketing, Human Genomics : Neurogenomics, Population Genomics | Leadership |
Shawna Owen | Associate Director, Global Commercial Support | Leadership |
Peter Perino | Director Distribution, Logistics, & Facilities | Leadership |
Nicole Jeleniowski | Director Of Finance | Leadership |
Alvin Hom | Head Of Global Talent Acquisition | Leadership |
Trang Dahlen | Senior Director, Segment Marketing, Global | Leadership |
Will Morrison | Vp, Global Legal | Leadership |
Michael Paumen | Head Of Japan | Leadership |
Amit Patel | Senior Director Product Marketing | Leadership |
Amber Stull | Director, Accounting | Leadership |
40 more people are available in the full profile.
Complete people profiles for Omniome
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Omniome
4 dated milestones of Omniome across 8 years, from founding to its latest funding, stage changes and deals.
- Founded Omniome is founded.
- Funding First funding round of $225K.
- Funding Latest funding round, Series C, of $60.0M.
- Exit Acquired by PacBio.
Competitors of Omniome
Omniome has 3 listed competitors in our database, 3 of them funded. They include PacBio, Complete Genomics and Bionano.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| pacb.com | 2004 | Menlo Park, United States | $395M | 649 | Instrument systems and software for single-molecule real-time sequencing are developed. | |
| completegenomics.com | 2006 | San Jose, United States | $124.99M | 70 | DNA sequencing platform for human genome analysis is developed. | |
| bionano.com | 2002 | San Diego, United States | $124.2M | Provider of genome analysis solutions to researchers and clinicians |
Detailed competitors of Omniome
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Omniome (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Omniome
Complete news archive for Omniome
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Omniome
Omniome was founded in 2013 and raised its 1st funding round 1 year after it was founded.
Omniome is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Dave Mullarkey is the CEO of Omniome, as recorded in our data.
Omniome is a funded company, having raised a total of $160.23M across 7 funding rounds to date. The company's 1st funding round was a Seed of $225K, raised on May 2014.
Omniome has 164 employees.
Omniome was founded in 2013 and is headquartered in San Diego, United States. The company operates in the biotechnology sector, offering a genome sequencing platform based on Sequencing By Binding (SBB) technology. This platform supports nucleotide and DNA matching for clinical samples, with applications in cancer diagnostics, single-cell sequencing, and analysis of genome regions susceptible to errors. Services are extended to various clinical sequencing needs.
Omniome's top competitors include PacBio, Complete Genomics and Bionano.
Omniome has 13 investors. Key investors include PacBio, Gates Foundation, Arch Venture Partners, Detong Capital, and Decheng Capital.
Omniome operates through Omniome, Inc..
Yes. Omniome was acquired by PacBio in July 2021.